Harbinger Venture

Harbinger Health is a biotechnology company dedicated to the early detection of cancer through a proprietary blood-based testing platform. Founded by Flagship Pioneering, the company leverages high-resolution epigenetics and machine learning to identify cancer-specific signals at their earliest stages. Their "H3" platform aims to provide affordable, accessible, and highly accurate screening for multiple cancer types, potentially transforming oncology from a reactive to a proactive field. Led by former FDA Commissioner Stephen Hahn, Harbinger Health is currently validating its technology through large-scale clinical studies like the CORE-Study.